Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: clinical results of a phase I clinical trial

被引：0
|
作者：
不详
机构：
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2006年 / 5卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：96 / 96
页数：1
相关论文
共 50 条
  • [1] Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells:: Results of a Phase I clinical trial
    Fuessel, Susanne
    Meye, Axel
    Schmitz, Marc
    Zastrow, Stefan
    Linne, Clemens
    Richter, Katja
    Loebel, Barbel
    Hakenberg, Oliver W.
    Hoelig, Kristina
    Rieber, E. Peter
    Wirth, Manfred P.
    PROSTATE, 2006, 66 (08): : 811 - 821
  • [2] Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells:: Results of a phase I clinical trial
    Fuessel, S.
    Meye, A.
    Schmitz, M.
    Zastrow, S.
    Linne, C.
    Richter, K.
    Lobel, B.
    Hakenberg, O. W.
    Hoelig, K.
    Rieber, E. P.
    Wirth, M. P.
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (14) : 801 - 801
  • [3] Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells:: Results of a phase I clinical trial.
    Fuessel, S
    Meye, A
    Schmitz, M
    Zastrow, S
    Linné, C
    Richter, K
    Hakenberg, OW
    Rieber, EP
    Wirth, MP
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9120S - 9120S
  • [4] Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: Immunological results of a phase I clinical trial
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 162 - 162
  • [5] Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: Results of a phase I clinical trial.
    Meye, A.
    Fuessel, S.
    Schmitz, M.
    Zastrow, S.
    Linne, C.
    Richter, K.
    Lobel, B.
    Hakenberg, O. W.
    Hoelig, K.
    Rieber, P. E.
    Wirth, M. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 112S - 112S
  • [6] INITIAL RESULTS FROM PHASE I/II TRIAL WITH DENDRITIC CELLS LOADED WITH AN ALLOGENEIC PROSTATE CANCER-LYSATE IN HORMONE-REFRACTORY PROSTATE CANCER PATIENTS
    Reyes, D.
    Lopez, M. N.
    Pereda, C.
    Aguilera, R.
    Salazar-Onfray, F.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 285 - 285
  • [7] Vaccination of patients with hormone-refractory prostate cancer using telomerase RNA transfected DC: Results from a phase I clinical trial.
    Su, Z
    Dannull, J
    Dahm, P
    Yang, B
    Coleman, D
    Yancey, D
    Sichi, S
    Higgins, J
    Gilboa, E
    Vieweg, J
    BLOOD, 2003, 102 (11) : 156A - 156A
  • [8] Transitory response to vaccination with PSCA-/PSA-peptide loaded, autologous dendritic cells in patients with metastatic, hormone-refractory prostate cancer
    AK Kaskel
    R Zeiser
    R Jochim
    W Schultze-Seemann
    CF Waller
    H Veelken
    Cancer Cell International, 4 (Suppl 1)
  • [9] Vaccination of patients with hormone-refractory prostate carcinoma with TH1-polarized PSA-peptide loaded dendritic cells
    Hildenbrand, B.
    Lorenzen, D.
    Kaiser, L.
    Freudenberg, M.
    Arnold, D.
    Azemar, M.
    ONKOLOGIE, 2013, 36 : 272 - 272
  • [10] Treatment of hormone refractory prostate cancer patients by vaccination with autologous dendritic cells pulsed with recombinant prostate specific membrane antigen: A Phase I/II clinical trial
    Elgamal, AAA
    Boynton, A
    Bosch, M
    Salgaller, M
    Lodge, PA
    Shankar, G
    Belldegrun, A
    Logothetis, C
    Papandreou, C
    JOURNAL OF UROLOGY, 2002, 167 (04): : 306 - 306
12345